Anyone in the industry who knows Ken Moch, the CEO of a little biotech in Durham, NC, named Chimerix, is likely to describe him as personable, chronically cheerful and an outspoken champion of all things Chimerix.
Anyone looking to start a biotech company should pay close attention to this list. Venture groups, entrepreneurs and increasingly Big Pharma have been concentrating their money and their attention in a few key places, only occasionally straying from the beaten path when funding a high-risk drug development effort.
The last 24 hours offered an important lesson over just how closely analysts and investors are tracking every movement on the immunotherapy front in cancer R&D.
Unlike every other Big Pharma company in the world, Novartis tends to prefer to communicate rather selectively when it chops a facility here or winnows out its ranks over there in its global structure.
Now that many of the major pharma companies have promised to open up, at least somewhat, on their clinical trial data, Novartis has decided to take the pledge as well. But rather than earn plaudits from longtime critics who have castigated the industry for years of secrecy about their clinical trials, it's only likely to stir a growing backlash among commentators who view these moves as far too limited, spurred primarily by a more ambitious approach from European regulators who want to force open the floodgates.
What should we make of the heavy, some would say unhealthy, concentration of drug R&D in certain hot categories like oncology and inflammation?
I've been in the U.K. for a few days now, grabbing some meetings along the way after discussing valuations in biotechnology with a group of One Nucleus members at The Babraham Institute near Cambridge. And I've been thinking about this question a lot this week.
Every year at FierceBiotech, our editors put together a list of powerful players, well-respected dealmakers and scientific luminaries in the life sciences industry, a group we deem to be the 25 most influential people in biopharma. This time, we want to hear from you, the reader.
Call it the JPMorgan effect. Every year at the beginning of January dealmakers from around the globe head to San Francisco to talk about biotech deals.
When Merck announced a massive shakeup of its R&D operations, the pharma giant left out any pesky details. But Wall Street Journal writers Peter Loftus and Jonathan Rockoff have come up with some of the first key brushstrokes of what they termed a "radical overhaul."